MedPath

Vaborbactam

Generic Name
Vaborbactam
Brand Names
Vabomere, Vaborem
Drug Type
Small Molecule
Chemical Formula
C12H16BNO5S
CAS Number
1360457-46-0
Unique Ingredient Identifier
1C75676F8V

Overview

Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of vaborbactam and Meropenem for intravenous administration. Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.

Background

Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of vaborbactam and Meropenem for intravenous administration. Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.

Indication

Indicated in combination with meropenem for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.

Associated Conditions

  • Complicated Urinary Tract Infection caused by Enterobacter cloacae
  • Complicated Urinary Tract Infection caused by Escherichia Coli
  • Complicated Urinary tract infection caused by klebsiella pneumoniae

FDA Approved Products

VABOMERE
Manufacturer:Melinta Therapeutics, LLC
Route:INTRAVENOUS
Strength:1 g in 2 g
Approved: 2023/09/30
NDC:70842-120

Singapore Approved Products

VABOREM POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1G/1G
Manufacturer:ACS DOBFAR S.P.A.
Form:INJECTION, POWDER, FOR SOLUTION
Strength:1 g
Online:Yes
Approved: 2025/04/25
Approval:SIN17224P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath